Evidence map›Paper›PMID 28150074›Full record

Trial reportInvestigational new drugs2017

A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

Satoru Miura, Makoto Maemondo, Akira Iwashima, Toshiyuki Harada, Shunichi Sugawara, Kunihiko Kobayashi, Akira Inoue, Taku Nakagawa, Yuichi Takiguchi, Hiroshi Watanabe and 5 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Investigational new drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Satoru MiuraDepartment of Internal Medicine, Niigata Cancer Center Hospital, 2-15-3, Kawagishicho, Chuo-ku, Niigata, 951-8566, Japan. miusat1118@niigata-cc.jp.ORCID 0000-0001-7868-6661
Makoto MaemondoDepartment of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
Akira IwashimaDepartment of Respiratory Medicine, Nagaoka Chuo General Hospital, Nagaoka, Japan.
Toshiyuki HaradaCenter for Respiratory Diseases, Japan Community Health Care Organization Hokkaido Hospital, Sapporo, Japan.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Kunihiko KobayashiDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Japan.
Akira InoueDepartment of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.
Taku NakagawaDepartment of Thoracic Surgery, Omagari Kosei Medical Center, Akita, Japan.
Yuichi TakiguchiDepartment of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroshi WatanabeDepartment of Respiratory Medicine, Saka General Hospital, Shiogama, Japan.
Takashi IshidaDepartment of Internal Medicine, Niigata Prefectural Central Hospital, Joetsu, Japan.
Masaki TeradaDepartment of Respiratory Medicine, Saiseikai Niigata Daini Hospital, Niigata, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine and Infectious Disease, Niigata University Medical and Dental Hospital, Niigata, Japan.
Akihiko GemmaDepartment of Pulmonary Medicine and Oncology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
Hirohisa YoshizawaDepartment of Respiratory Medicine and Infectious Disease, Niigata University Medical and Dental Hospital, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The efficacy and safety of bevacizumab in elderly patients with non-small cell lung cancer remain controversial. This study focused on both selecting fit elderly patients and overcoming interpatient variability with respect to pharmacodynamics. Methods Elderly (age: ≥70 years) patients with advanced non-squamous non-small cell lung cancer were enrolled. Patients with uncontrolled congestive heart failure and uncontrolled diabetes were excluded. The treatment regimen comprised carboplatin at an area under the curve of 5 mg/ml/min on day 1, paclitaxel at 90 mg/m

Indexed as

AgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCarcinoma, Non-Small-Cell LungFemaleHumansKaplan-Meier EstimateLung NeoplasmsMalePaclitaxelTreatment OutcomeAntineoplastic AgentsBevacizumabCarboplatinPaclitaxelBevacizumabElderly patientsNon-small cell lung cancerNon-squamous histologyPatient selection

Identifiers

PMID28150074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.